FindTrial
Sign In

Clinical Study of Qingjin Huatan Decoction in Treating Patients with Acute Exacerbation of Bronchiectasis of the Phlegm-Heat Obstructing Lung Pattern

Clinical Research on Qingjin Huatan Decoction for the Treatment of Bronchiectasis with Infection(Phlegm-Heat Congestion Syndrome)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000723
Enrollment
Unknown
Registered
2026-03-25
Start date
2025-06-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis

Interventions

experimental group:administer Qingjin Huatan Decoction orallytake Qingjin Huatan Decoction orally
control group:conventional Western medicine treatment

Sponsors

Jiangsu Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Clinically diagnosed with acute exacerbation of bronchiectasis.(2) Traditional Chinese Medicine (TCM) syndrome differentiation conforms to the pattern of phlegm-heat obstructing the lung.(3) Aged between 18 and 75 years.(4) Informed about the trial and having signed the informed consent form.(5) No severe complications such as cardiovascular liver or kidney diseases with stable vital signs and normal comprehension ability.(6) No use of other antibiotics or traditional Chinese herbal medicines during the current episode of illness.(7) White blood cell count in the complete blood count greater than 10×10^9/L.

Exclusion criteria

Exclusion criteria: (1)Those who do not meet the diagnostic criteria of either Traditional Chinese Medicine(TCM)or Western medicine. (2)Bronchiectasis caused by congenital diseases or functional defects. (3)Individuals with allergic constitutions or those allergic to the study medication in this trial. (4)Pregnant or breastfeeding womenor those with mental disorders. (5)Patients with other severe comorbidities. (6)Those who have received other relevant treatments that may affect the observation indicators of this trial. (7)Patients with hemoptysis exceeding 100 ml in 24 hours.

Design outcomes

Primary

MeasureTime frame
White Blood Cell Count;Efficacy of Traditional Chinese Medicine(TCM)Syndrome;—

Secondary

MeasureTime frame
Quality of Life Score for Patients with Bronchiectasis;Modified Medical Research Council Dyspnea Scale;Chronic Obstructive Pulmonary Disease Assessment Test;—

Countries

China

Contacts

Public ContactHailang He

Affiliated Hospital of Nanjing University of Chinese Medicine

1902674346@qq.com15778131708

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026